Statins considered safe for children with hereditary high cholesterol levels

Statins considered safe for children with hereditary high cholesterol levels

January 18 2018 A new study has found no statin-related safety issues for statins being used to...

Drug Safety Update includes eluxadoline, fingolimod

Drug Safety Update includes eluxadoline, fingolimod

December 19 2017 The MHRA’s latest Drug Safety Update includes information about two black...

Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

December 13 2017 Women using hormonal contraceptives are exposed to a 20% increased risk of...

MHRA issues new batch of Drug Safety Update notices

MHRA issues new batch of Drug Safety Update notices

November 28 2017 The medicines regulator has issued four Drug Safety Updates relating to...

Vitamin D intake guidance for pregnant mums and babies updated in Scotland

Vitamin D intake guidance for pregnant mums and babies updated in Scotland

November 27 2017 NHS Scotland has updated its recommendations around vitamin D intake for new...

  • Statins considered safe for children with hereditary high cholesterol levels

    Statins considered safe for children with hereditary high cholesterol levels

    Thursday, 18 January 2018 11:07
  • Drug Safety Update includes eluxadoline, fingolimod

    Drug Safety Update includes eluxadoline, fingolimod

    Tuesday, 19 December 2017 10:16
  • Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

    Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

    Wednesday, 13 December 2017 12:33
  • MHRA issues new batch of Drug Safety Update notices

    MHRA issues new batch of Drug Safety Update notices

    Tuesday, 28 November 2017 09:52
  • Vitamin D intake guidance for pregnant mums and babies updated in Scotland

    Vitamin D intake guidance for pregnant mums and babies updated in Scotland

    Monday, 27 November 2017 14:50

a man taking medication imageNovember 10 2017

Doxycycline should not be used for post-exposure prophylaxis (PEP) for sexually transmitted infections, says new guidance. Any potential benefits are “outweighed by the considerable potential for antibiotic resistance to develop in STIs and other bacteria.”

Members of the public who may be searching online for doxycycline PEP should be advised that antibiotics should only be prescribed by a health professional and use diagnostic testing.

A position statement issued jointly by Public Health England and the British Association for Sexual Health and HIV (BASHH) says more research is needed to assess the wider impact of prophylactic doxycycline on antimicrobial resistance (AMR) at an individual and population level. Instead, the organisations state: “We recommend the use of antibiotics as prescribed by a healthcare professional and as indicated by the results of a suitable diagnostic test.”

The statement refers to a study published earlier this year which had found that doxycycline PEP had halved the rates of bacterial STIs in men who have sex with men (MSM), in an extension of the French IPERGAY trial. “Many of the online companies selling HIV Pre-exposure Prophylaxis (PrEP) in the form of tenofovir disoproxil fumarate 300mg / emtricitabine 200mg are now making doxycycline available to UK buyers,” says the statement.

“A high rate of STIs without doxycycline PEP was shown (69.7 events per 100-person years of follow-up) and the antibiotic strategy showed an overall reduction in STI incidence of 47%. There was a significant decrease in chlamydia and syphilis incidence with reductions of 70 and 73% respectively in intent to treat analyses but no clear benefit was shown for gonorrhoea, likely due to the high rate of doxycycline resistance already developed.”

The PHE /BASHH statement adds: “For those at risk, following condomless sex, we recommend STI testing at appropriate window periods and the treatment of any infections identified should be prescribed by a healthcare professional and be in line with published national guidance. We recommend that the use of doxycycline PEP should be restricted to the research setting at present.”

Links:
PHE announcement       
BASHH announcement  
PHE/BASHH ‘Position Statement on Doxycycline as PostExposure Prophylaxis for Sexually Transmitted Infections’ November 2017                  

Clinical News

January 22 2018 An updated respiratory health plan for Wales has been published, taking forward the national strategy for the next three years.